Eris Lifesciences stated that its consolidated net profit increased 12 per cent to Rs 101 crore for the third quarter ended December 2021.
The company stated that the revenue stood at Rs 332 crore in the third quarter of the current fiscal as against Rs 310 crore in the year-ago period, Eris Lifesciences said.
''Our focus on building leadership brands in fast-growing therapies coupled with several patent expiration opportunities will enable us to sustain our growth trajectory,'' stated Eris Lifesciences Chairman & Managing Director Amit Bakshi.
(With inputs from PTI)
Resident Doctors Begin Indefinite Strike Across Himachal Pradesh After Termination Of Colleague Over Viral Video
National Consumer Helpline Secures ₹45 Crore Refunds In 8 Months, E-Commerce Tops With ₹32 Crore
'Isolated Incident': Indian Immunologicals Limited Issues Clarification After Australia's Advisory On Counterfeit Anti-Rabies Vaccine Abhayrab
Battle Of Galwan Teaser: Salman Khan Fans Are In For Treat On Superstar's Birthday - Watch
